Table 1.
Patient demographic and disease characteristics at diagnosis, overall (2004–2018), and by first-line treatment initiation period (pre- and post-2010).
| Perioda | 2004–2018 | Pre-2010 | Post-2010 |
|---|---|---|---|
| Patients, N | 4480 | 1415 | 3065 |
| Gender, N (%)b | |||
| Male | 2615 (58.4) | 819 (57.9) | 1796 (58.6) |
| Female | 1865 (41.6) | 596 (42.1) | 1269 (41.4) |
| Male/female ratio | 1.4/1 | 1.4/1 | 1.4/1 |
| Age, years | |||
| Patients, N | 4479 | 1415 | 3064 |
| Mean (SD) | 64.4 (10.2) | 63.6 (10.4) | 64.8 (10.1) |
| Median | 65.0 | 64.0 | 66.0 |
| Min–Max | 29.0–91.0 | 30.0–89.0 | 29.0–91.0 |
| Q1–Q3 | 57.0–72.0 | 56.0–71.0 | 58.0–72.0 |
| Age groups, N (%)b | |||
| Reported | 4479 | 1415 | 3064 |
| <60 years | 1386 (30.9) | 484 (34.2) | 902 (29.4) |
| 60–64 years | 704 (15.7) | 227 (16.0) | 477 (15.6) |
| 65–74 years | 1661 (37.1) | 494 (34.9) | 1167 (38.1) |
| ≥75 years | 728 (16.3) | 210 (14.8) | 518 (16.9) |
| Not reported | 1 (0.0) | – | 1 (0.0) |
| Time from first symptoms to diagnosis, months | |||
| Patients, N | 967 | 258 | 709 |
| Mean (SD) | 11.7 (22.4) | 12.0 (23.2) | 11.6 (22.1) |
| Median | 5.1 | 5.4 | 5.0 |
| Min–Max | 0.0–244.9 | 0.0–244.9 | 0.0–236.5 |
| Q1–Q3 | 1.3–12.4 | 1.1–13.0 | 1.4–12.0 |
| Time from diagnosis to first–line treatment, months | |||
| Patients, N | 4360 | 1401 | 2959 |
| Mean (SD) | 1.5 (3.8) | 1.5 (2.6) | 1.5 (4.2) |
| Median | 0.7 | 0.7 | 0.8 |
| Min–Max | 0.0–80.8 | 0.0–34.0 | 0.0–80.8 |
| Q1–Q3 | 0.5–1.4 | 0.5–1.5 | 0.5–1.4 |
| Mayo2004/European cardiac stage, N (%)b | |||
| Reported | 3775 (84.3) | 859 (60.7) | 2916 (95.1) |
| I | 696 (18.4) | 184 (21.4) | 512 (17.6) |
| II | 1413 (37.4) | 347 (40.4) | 1066 (36.6) |
| IIIa | 1003 (26.6) | 150 (17.5) | 853 (29.3) |
| IIIb | 663 (17.6) | 178 (20.7) | 485 (16.6) |
| Not reported | 705 (15.7) | 556 (39.3) | 149 (4.9) |
| Revised stage (Mayo2012), N (%)b | |||
| Reported | 3065 (68.4) | 652 (46.1) | 2413 (78.7) |
| I | 608 (19.8) | 157 (24.1) | 451 (18.7) |
| II | 743 (24.2) | 163 (25.0) | 580 (24.0) |
| III | 896 (29.2) | 157 (24.1) | 739 (30.6) |
| IV | 818 (26.7) | 175 (26.8) | 643 (26.6) |
| Not reported | 1415 (31.6) | 763 (53.9) | 652 (21.3) |
| Organ involvement, N (%)b,c | |||
| Heart | 3041 (67.9) | 906 (64.0) | 2135 (69.7) |
| Kidneys | 2961 (66.1) | 937 (66.2) | 2024 (66.0) |
| Soft tissue | 802 (17.9) | 193 (13.6) | 609 (19.9) |
| Nervous system | 646 (14.4) | 199 (14.1) | 447 (14.6) |
| Liver | 640 (14.3) | 231 (16.3) | 409 (13.3) |
| Gastrointestinal tract | 283 (6.3) | 68 (4.8) | 215 (7.0) |
| Lung | 39 (0.9) | 13 (0.9) | 26 (0.9) |
| Number of organs involved, N (%)b | |||
| Reported | 4329 (96.6) | 1282 (90.6) | 3047 (99.4) |
| 1 | 1536 (35.5) | 413 (32.2) | 1123 (36.9) |
| 2 | 1784 (41.2) | 560 (43.7) | 1224 (40.2) |
| ≥3 | 1009 (23.3) | 309 (24.1) | 700 (23.0) |
| Not reported | 151 (3.4) | 133 (9.4) | 18 (0.6) |
| ECOG PS, N (%)b | |||
| Reported | 3432 (76.6) | 728 (51.4) | 2704 (88.2) |
| 0 | 623 (18.2) | 70 (9.6) | 553 (20.5) |
| 1 | 1411 (41.1) | 289 (39.7) | 1122 (41.5) |
| 2 | 1010 (29.4) | 221 (30.4) | 789 (29.2) |
| 3 | 362 (10.5) | 131 (18.0) | 231 (8.5) |
| 4 | 26 (0.8) | 17 (2.3) | 9 (0.3) |
| Not reported | 1048 (23.4) | 687 (48.6) | 361 (11.8) |
ECOG PS Eastern Cooperative Oncology Group performance status, Max maximum value, Min minimum value, N number of patients, Q1 first quartile, Q3 third quartile, SD standard deviation.
aPre- and post-2010 indicate the periods of 2004–2010 and 2011–2018, respectively.
bPercentages are calculated using the total number of patients with available data in each column as the denominator.
cPatients could have >1 involved organs.